glucose, (beta-d)-isomer has been researched along with natriuretic peptide, brain in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 16 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Bengtsson, O; DeMets, DL; Inzucchi, SE; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Ponikowski, P; Sabatine, MS; Sjöstrand, M; Solomon, SD | 2 |
| Chang, CY; Chen, WY; Chen, YF; Dai, ZK; Jhuang, WJ; Jhuo, SJ; Lee, AS; Lee, HC; Liu, PL; Shiou, YL | 1 |
| Bruun, NE; Fosbøl, E; Frederiksen, PH; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Bengtsson, O; Chiang, CE; DeMets, DL; Dutkiewicz-Piasecka, M; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Langkilde, AM; Martinez, FA; McMurray, JJV; Nicolau, JC; Petrie, MC; Ponikowski, P; Sabatine, MS; Serenelli, M; Sjöstrand, M; Solomon, SD; Tereshchenko, S | 1 |
| Ablasser, K; Alber, H; Berger, R; Kaulfersch, C; Kolesnik, E; Leitner, K; Lichtenauer, M; Mader, A; Moertl, D; Oulhaj, A; Pferschy, PN; Reiter, C; Rieder, T; Saely, CH; Sailer, S; Siller-Matula, J; Sourij, H; Tripolt, NJ; Verheyen, N; von Lewinski, D; Weidinger, F; Zechner, PM | 1 |
| Beusekamp, JC; Boorsma, EM; Damman, K; Elvan, A; Heerspink, HJL; Smilde, TDJ; Swart, HP; van Eck, JWM; Voors, AA | 1 |
| Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y | 1 |
| Bruun, NE; Brønd, JC; Faber, J; Forman, JL; Fosbøl, EL; Gustafsson, F; Gustafsson, I; Jensen, J; Kistorp, C; Køber, L; Møller, JE; Omar, M; Poulsen, MK; Schou, M; Tuxen, C; Videbæk, L | 1 |
| Feng, X; Gao, G; Gu, Q; Li, Q; Yuan, L; Zhang, Y | 1 |
| Kosiborod, MN; McGuire, DK; Verma, S | 1 |
| Aaron, M; Collins, SP; Cox, ZL; Davidson, BT; Fowler, M; Hernandez, GA; Iii, ATM; Jenkins, CA; Jr, FEH; Kampe, C; Lindenfeld, J; Lindsell, CJ; Miller, KF; Stubblefield, WB | 1 |
| Anker, SD; Bocchi, E; Böhm, M; Brueckmann, M; Brunner-La Rocca, HP; Butler, J; Choi, DJ; Chopra, V; Chuquiure, E; Ferreira, JP; Filippatos, G; Giannetti, N; Gomez-Mesa, JE; Gonzalez-Juanatey, JR; Jamal, W; Janssens, S; Januzzi, JL; Merkely, B; Nicholls, SJ; Packer, M; Perrone, SV; Piña, IL; Pocock, SJ; Ponikowski, P; Schnaidt, S; Schnee, JM; Senni, M; Seronde, MF; Shahzeb Khan, M; Sim, D; Spinar, J; Squire, I; Taddei, S; Tsutsui, H; Verma, S; Vinereanu, D; Zannad, F; Zhang, J | 1 |
| Abe, M; Fujikawa, K; Fujita, Y; Fukunami, M; Furukawa, Y; Hata, M; Kawahira, M; Kawai, T; Kawasaki, M; Kayama, K; Kikuchi, A; Morita, T; Nakamura, J; Sanada, S; Seo, M; Shintani, A; Tamaki, S; Tanabe, K; Taniuchi, S; Umayahara, Y; Watanabe, T; Yamada, T; Yamamoto, K | 1 |
| Higashi, Y; Node, K; Okada, Y; Shimabukuro, M; Taguchi, I; Takamura, T; Tanaka, A; Teragawa, H; Tomiyama, H; Toyoda, S; Ueda, S | 1 |
| Bayés-Genís, A; de la Espriella, R; Lorenzo, M; Miñana, G; Núñez, E; Núñez, G; Núñez, J; Santas, E | 1 |
| Anker, SD; Butler, J; Cotton, D; Ferreira, JP; Filippatos, G; Iwata, T; Januzzi, JL; Packer, M; Pocock, SJ; Sattar, N; Schnee, J; Vedin, O; Verma, S; Zannad, F | 1 |
| Hamaoka, T; Hirai, T; Inoue, O; Kato, T; Kawashiri, MA; Mukai, Y; Murai, H; Sakata, K; Sugimoto, H; Takamura, M; Takashima, S; Takata, S; Usui, S | 1 |
| Adamson, C; Bengtsson, O; Butt, JH; de Boer, RA; Docherty, KF; Inzucchi, SE; Jhund, PS; Kosiborod, MN; Køber, L; Lindholm, D; Maria Langkilde, A; Martinez, FA; McMurray, JJV; O'Meara, E; Petrie, MC; Ponikowski, P; Sabatine, MS; Schou, M; Sjöstrand, M; Solomon, SD | 1 |
| Barbancho, MA; Bernal-López, MR; Gómez-Huelgas, R; Jiménez-Navarro, M; Lara, JP; López-Carmona, MD; López-Sampalo, A; Millán-Gómez, M; Osuna-Sánchez, J; Pérez-Belmonte, LM; Ricci, M; Sanz-Cánovas, J | 1 |
| Akasaka, H; Fujio, Y; Fukuda, M; Iwakura, K; Kamide, K; Nakatani, S; Ogihara, T; Okamura, A; Rakugi, H; Shintani, A; Sugimoto, K; Takiuchi, S; Taniuchi, S; Yamamoto, K | 1 |
1 review(s) available for glucose, (beta-d)-isomer and natriuretic peptide, brain
| Article | Year |
|---|---|
Two Tales: One Story: EMPEROR-Reduced and DAPA-HF.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Kidney Diseases; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
14 trial(s) available for glucose, (beta-d)-isomer and natriuretic peptide, brain
| Article | Year |
|---|---|
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Hospitalization; Humans; Natriuretic Peptide, Brain; Patient Reported Outcome Measures; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Quality of Life; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2019 |
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics.
Topics: Aged; Benzhydryl Compounds; Diabetes Complications; Female; Glucosides; Glycated Hemoglobin; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prediabetic State; Reference Values; Registries; Treatment Outcome | 2019 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebo Effect; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Ventricular Function, Left; Young Adult | 2020 |
Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Echocardiography; Glucosides; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Ketone Bodies; Length of Stay; Mortality; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
Topics: Aged; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Treatment Outcome | 2020 |
Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
Topics: Accelerometry; Activities of Daily Living; Benzhydryl Compounds; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Outcome Assessment, Health Care; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Dysfunction, Left | 2020 |
The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Atrial Natriuretic Factor; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Young Adult | 2020 |
Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial.
Topics: Acute Disease; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Disease Progression; Glucosides; Heart Failure; Hospital Mortality; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Hypotension; Hypovolemia; Insulin; Natriuresis; Natriuretic Peptide, Brain; Patient Readmission; Peptide Fragments; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Cardiovascular Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume | 2020 |
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; COVID-19; Creatinine; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Female; Glucosides; Heart Failure; Hospitalization; Humans; Japan; Kidney; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2021 |
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluid Shifts; Glucosides; Humans; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Water-Electrolyte Balance | 2021 |
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial.
Topics: Aged; Benzhydryl Compounds; Female; Glucosides; Heart Failure, Systolic; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study.
Topics: Aged; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Thiophenes; Ventricular Function, Left | 2022 |
7 other study(ies) available for glucose, (beta-d)-isomer and natriuretic peptide, brain
| Article | Year |
|---|---|
Drugs in traffic: the road to approval.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abiraterone Acetate; Adenine; Androstadienes; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Benzhydryl Compounds; Bevacizumab; Drug Approval; Drug Industry; Glucosides; Hydroxyprogesterones; Indans; Morpholines; Natriuretic Peptide, Brain; Organophosphonates; Protein C; Recombinant Proteins; Rivaroxaban; Tenofovir; Thiophenes | 2011 |
The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Topics: Animals; Atrial Function, Left; Atrial Natriuretic Factor; Benzhydryl Compounds; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Fibrosis; Gene Expression Regulation; Glucosides; Heart Failure; Hemodynamics; Hypertension; Male; Myocardium; Natriuretic Peptide, Brain; Rats, Inbred SHR; Rats, Inbred WKY; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure.
Topics: Benzhydryl Compounds; Biomarkers; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Retrospective Studies | 2021 |
Different Responses of Muscle Sympathetic Nerve Activity to Dapagliflozin Between Patients With Type 2 Diabetes With and Without Heart Failure.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Muscles; Natriuretic Peptide, Brain; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Sympathetic Nervous System | 2021 |
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Topics: Aged; Atrial Fibrillation; Benzhydryl Compounds; Clinical Trials as Topic; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left | 2021 |
Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diuretics; Glucosides; Heart Failure; Hospitalization; Humans; Insulins; Natriuretic Peptide, Brain; Peptide Fragments; Sodium-Glucose Transporter 2 Inhibitors | 2022 |